NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Effect of Stomach Acid on Foscarnet

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 6

Registration Number: NCT00000964

Locations: 🇺🇸
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States

A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

Phase 1

Completed

Conditions: HIV Infections
Pregnancy

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 26

Registration Number: NCT00000878

Locations: 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸
Univ of Chicago Children's Hosp, Chicago, Illinois, United States
🇺🇸
Children's Hosp of Boston, Boston, Massachusetts, United States

and more 17 locations

A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients

Not Applicable

Completed

Conditions: HIV Infections
Leukoencephalopathy, Progressive Multifocal

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00000945

Locations: 🇺🇸
Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸
San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸
Univ of Alabama at Birmingham, Birmingham, Alabama, United States

and more 16 locations

A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection

Phase 2

Completed

Conditions: HIV Infections
Peripheral Nervous System Disease

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 240

Registration Number: NCT00000793

Locations: 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸
Hosp. of the Univ. of Pennsylvania CRS, Philadelphia, Pennsylvania, United States
🇺🇸
Northwestern University CRS, Chicago, Illinois, United States

and more 34 locations

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT00000866

Locations: 🇺🇸
JHU AVEG, Baltimore, Maryland, United States
🇺🇸
St. Louis Univ. School of Medicine AVEG, Saint Louis, Missouri, United States
🇺🇸
Vanderbilt Univ. Hosp. AVEG, Nashville, Tennessee, United States

and more 1 locations

The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1900

Registration Number: NCT00000861

Locations: 🇺🇸
Southern New Jersey AIDS Cln Trials / Dept of Med, Camden, New Jersey, United States
🇺🇸
Veterans Administration Med Ctr / Regional AIDS Program, Washington, District of Columbia, United States
🇺🇸
North Jersey Community Research Initiative, Newark, New Jersey, United States

and more 11 locations

Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-11-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 92

Registration Number: NCT00013663

Locations: 🇺🇸
New York Hosp - Cornell Med Ctr, New York, New York, United States

Recombinant Human IL-4 Receptor Used in Treatment of Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Biological: Recombinant human soluble IL-4 receptor
Biological: Placebo for Recombinant human soluble IL-4 receptor

First Posted Date: 2001-08-31

Last Posted Date: 2016-03-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 62

Registration Number: NCT00017693

The Biology of HIV Transmission

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2015-10-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT00001092

Locations: 🇺🇸
Cedars Sinai Med Ctr, Los Angeles, California, United States
🇺🇸
UCSD, San Diego, California, United States
🇺🇸
San Francisco Gen Hosp / UCSF AIDS Program, San Francisco, California, United States

Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis

Not Applicable

Completed

Conditions: Tuberculosis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2011-03-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT00000950

Locations: 🇺🇸
Emory Univ, Atlanta, Georgia, United States
🇺🇸
Beth Israel Med Ctr, New York, New York, United States
🇺🇸
Queens Med Ctr, Honolulu, Hawaii, United States

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy